Compare Thomson Reuters Corp (TRI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs 10X Genomics Inc — how do they compare? Thomson Reuters Corp trades at $90.98 (market cap $41.28B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Thomson Reuters Corp is far larger — about 7.5× 10X Genomics Inc's market cap, and Thomson Reuters Corp pays a 2.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TRI | TXG | |
|---|---|---|
Market Cap | $41.28B | $5.48B |
Sector | Industrials | Health |
52-Week High | $205.54 | $45.80 |
52-Week Low | $76.55 | $11.34 |
Enterprise Value | $43.24B | $5.02B |
Dividend Yield | 2.75% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
